A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

INCLUSION CRITERIA:

• Current diagnosis of probable Alzheimer's disease.
• ADAS-cog score of at least 12 and MMSE score of 10 to 26.
• Non-smoker
• Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person.
• Fluent in English.

EXCLUSION CRITERIA:

• Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks.
• Has clinically significant or uncontrolled medical condition other than Alzheimer's disease.
• Nursing home resident.